Nasdaq

New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life

Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to significant reductions in glycated hemoglobin (HbA1c ...
Nasdaq

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also ...
MobiHealthNews

Abbott's FreeStyle Libre 2 CGM picks up Medicare coverage

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...
MobiHealthNews

Abbott finally gets FDA greenlight for FreeStyle Libre 2

This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes. The ...
Monthly Prescribing Reference

FDA Clears FreeStyle Libre 2 App to Monitor Glucose Levels

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...